NCT06682780

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

An Open-label, Dose-escalation, and Dose-expansion Phase I/II Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of LM-2417 for Injection Alone or in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 320 (estimated)
• Sponsor: LaNova Medicines Limited · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	LM-2417	Q2W/Q3W,Intravenous Drip
DRUG	Docetaxel	Q3W,Intravenous Drip
DRUG	Toripalimab/Tirelizumab	Q3W,Intravenous Drip
DRUG	Carboplatin	Q3W,Intravenous Drip
DRUG	Niraparib	QD,Oral Administration
DRUG	Lenvatinib	QD,Oral Administration

Timeline

• Start date: 2025-09-17
• Primary completion: 2028-12-25
• Completion: 2029-12-01
• First posted: 2024-11-12
• Last updated: 2025-09-25

Locations

1 site across 1 country: China